Vor Biopharma Inc.

NasdaqGS:VOR 株式レポート

時価総額:US$54.3m

Vor Biopharma 将来の成長

Future 基準チェック /26

Vor Biopharmaは、9.8%と78.3%でそれぞれ年率9.8%で利益と収益が成長すると予測される一方、EPSはgrowで22.4%年率。

主要情報

9.8%

収益成長率

22.4%

EPS成長率

Biotechs 収益成長28.3%
収益成長率78.3%
将来の株主資本利益率n/a
アナリストカバレッジ

Good

最終更新日21 Nov 2024

今後の成長に関する最新情報

Recent updates

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

Sep 10
Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 24
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Dec 05
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Aug 18
Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

May 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

Mar 13
Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Oct 19
We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Vor Bio appoints Eyal C. Attar as chief medical officer

Oct 12

Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Jun 18
Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Mar 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Aug 30
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma: Targeted Therapies For Transplants

Jun 30

We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 10
We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma EPS misses by $0.03

May 06

業績と収益の成長予測

NasdaqGS:VOR - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20268-122-84-1326
12/31/20251-115-115-1117
12/31/2024N/A-114-116-1017
9/30/2024N/A-112-100-100N/A
6/30/2024N/A-118-105-104N/A
3/31/2024N/A-120-108-106N/A
12/31/2023N/A-118-101-100N/A
9/30/2023N/A-116-96-95N/A
6/30/2023N/A-106-87-86N/A
3/31/2023N/A-98-93-87N/A
12/31/2022N/A-92-94-85N/A
9/30/2022N/A-86-94-84N/A
6/30/2022N/A-81-92-83N/A
3/31/2022N/A-78-79-74N/A
12/31/2021N/A-70-73-69N/A
9/30/2021N/A-70-69-65N/A
6/30/2021N/A-65-61-56N/A
3/31/2021N/A-56-53-48N/A
12/31/2020N/A-49-40-36N/A
9/30/2020N/A-36-31-28N/A
6/30/2020N/A-26-25-23N/A
3/31/2020N/A-19-17-15N/A
12/31/2019N/A-13-11-10N/A

アナリストによる今後の成長予測

収入対貯蓄率: VOR今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VOR今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: VOR今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VORの収益 ( 78.3% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: VORの収益 ( 78.3% ) 20%よりも速いペースで成長すると予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: VORの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘